We sought to identify risk factors for insulin resistance, metabolic syndrome (MetS), and diabetes mellitus in 248 non-Hispanic white HFE C282Y homozygotes identified by population screening.
Methods:
We analyzed observations obtained prospectively in a postscreening examination: age; sex; body mass index (BMI); systolic/diastolic blood pressure; metacarpophalangeal (MP) joint hypertrophy; hepatomegaly; complete blood counts; alanine/aspartate aminotransferase levels; elevated C-reactive protein (>0.5 mg/dL); transferrin saturation; serum ferritin; homeostasis model assessment-insulin resistance (HOMA-IR); and MetS.
Results:
Twenty-six participants (10.5%) had diabetes diagnoses. A significant trend across HOMA-IR quartiles was observed only for blood neutrophils. Logistic regression on HOMA-IR fourth quartile revealed positive associations: age (P = 0.0002); male sex (P = 0.0022); and BMI (P < 0.0001). HOMA-IR fourth quartile predicted MetS (P < 0.0001). Logistic regression on diabetes revealed positive associations: age (P = 0.0012); male sex (P = 0.0068); MP joint hypertrophy (P = 0.0167); neutrophils (P = 0.0342); and MetS (P = 0.0298). Serum ferritin did not predict HOMA-IR fourth quartile, MetS, or diabetes.
Conclusions:
In screening C282Y homozygotes, age, male sex, and BMI predicted HOMA-IR fourth quartile. HOMA-IR fourth quartile alone predicted MetS. Diabetes was associated with greater age, male sex, MP joint hypertrophy, greater blood neutrophil counts, and MetS.
Get full access to this article
View all access options for this article.
References
1.
FederJN, GnirkeA, ThomasW, et al.A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet, 1996; 13:399–408.
2.
AdamsPC, ReboussinDM, BartonJC, et al.Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med, 2005; 352:1769–1778.
3.
BartonJC, EdwardsCQ, PhatakPD, et al.Complications of hemochromatosis and iron overload. In BartonJC, EdwardsCQ, PhatakPD, et al. (eds.): Handbook of Iron Overload Disorders. Cambridge, MA: Cambridge University Press. 2010: 65–107.
4.
McClainDA, AbrahamD, RogersJ, et al.High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia, 2006; 49:1661–1669.
5.
O'SullivanEP, McDermottJH, MurphyMS, et al.Declining prevalence of diabetes mellitus in hereditary haemochromatosis—the result of earlier diagnosis. Diabetes Res Clin Pract, 2008; 81:316–320.
6.
BartonJC, BartonJC, ActonRT. Diabetes in first-degree family members: A predictor of type 2 diabetes in 159 nonscreening Alabama hemochromatosis probands with HFE C282Y homozygosity. Diabetes Care, 2014; 37:259–266.
7.
TrousseauA. Glycosurie, diabète sucre. Clinique médicale de l'Hôtel-Dieu de Paris, 1865; 2:663–698.
8.
OlynykJK, CullenDJ, AquiliaS, et al.A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med, 1999; 341:718–724.
9.
DymockIW, CassarJ, PykeDA, et al.Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am J Med, 1972; 52:203–210.
NiederauC, BergerM, StremmelW, et al.Hyperinsulinaemia in non-cirrhotic haemochromatosis: Impaired hepatic insulin degradation?. Diabetologia, 1984; 26:441–444.
12.
SheldonJH. Haemochromatosis. Oxford: Oxford University Press. 1935.
13.
FinchSC, FinchCA. Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis. Medicine (Baltimore), 1955; 34:381–430.
14.
BalcerzakSP, MintzDH, WestermanMP. Diabetes mellitus and idiopathic hemochromatosis. Am J Med Sci, 1968; 255:53–62.
15.
DymockIW, WilliamsR. Haemochromatosis and diabetes. Postgrad Med J, 1971; Suppl:79–83.
16.
McLarenGD, McLarenCE, AdamsPC, et al.Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol, 2008; 22:923–930.
17.
MatthewsDR, HoskerJP, RudenskiAS, et al.Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412–419.
18.
McLarenCE, BartonJC, AdamsPC, et al.Hemochromatosis and Iron Overload Screening (HEIRS) Study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci, 2003; 325:53–62.
19.
ActonRT, BartonJC, SnivelyBM, et al.Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Ethn Dis, 2006; 16:815–821.
20.
EdwardsCQ, BartonJC. Hemochromatosis. In GreerJP, ArberDA, GladerB, et al. (eds.): Wintrobe's Clinical Hematology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2014:662–681.
21.
van StraalenJP, LeyteA, WeberJA, et al.Evaluation of the Hitachi 911 for routine urine analysis and for measurement of various special serum analytes. Eur J Clin Chem Clin Biochem, 1995; 33:315–322.
22.
LaaksonenDE, LakkaHM, NiskanenLK, et al.Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol, 2002; 156:1070–1077.
23.
FordES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care, 2005; 28:2745–2749.
24.
ActonRT, BartonJC, BartonJC. Serum ferritin, insulin resistance, and metabolic syndrome: Clinical and laboratory associations in 769 non-hispanic whites without diabetes mellitus in the HEIRS Study. Metab Syndr Relat Disord, 2015; 13:57–63.
25.
ShinJA, LeeJH, LimSY, et al.Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Invest, 2013; 4:334–343.
26.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001; 285:2486–2497.
27.
AlbertiKG, ZimmetP, ShawJ. The metabolic syndrome—a new worldwide definition. Lancet, 2005; 366:1059–1062.
28.
AlbertiKG, EckelRH, GrundySM, et al.Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009; 120:1640–1645.
29.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2013; 36Suppl 1:S67–S74.
30.
RoweJW, MinakerKL, PallottaJA, et al.Characterization of the insulin resistance of aging. J Clin Invest, 1983; 71:1581–1587.
31.
KimmerlingG, JavorskiWC, ReavenGM. Aging and insulin resistance in a group of nonobese male volunteers. J Am Geriatr Soc, 1977; 25:349–353.
32.
PaganoG, CassaderM, DianaA, et al.Insulin resistance in the aged: The role of the peripheral insulin receptors. Metabolism, 1981; 30:46–49.
33.
LonnrothP, SmithU. Aging enhances the insulin resistance in obesity through both receptor and postreceptor alterations. J Clin Endocrinol Metab, 1986; 62:433–437.
34.
FaerchK, Borch-JohnsenK, VaagA, et al.Sex differences in glucose levels: A consequence of physiology or methodological convenience? The Inter99 study. Diabetologia, 2010; 53:858–865.
35.
GeerEB, ShenW. Gender differences in insulin resistance, body composition, and energy balance. Gend Med, 2009; 6Suppl 1:60–75.
36.
SamaanMC, AnandSS, SharmaAM, et al.Sex differences in skeletal muscle phosphatase and tensin homolog deleted on chromosome 10 (PTEN) levels: A cross-sectional study. Sci Rep, 2015; 5:9154.
37.
Garca-EstevezDA, Araujo-VilarD, Saavedra-GonzalezA, et al.Analysis of the relationship between body mass index, insulin resistance, and beta-cell function: A cross-sectional study using the minimal model. Metabolism, 2004; 53:1462–1466.
38.
RiserusU, ArnlovJ, BerglundL. Long-term predictors of insulin resistance: Role of lifestyle and metabolic factors in middle-aged men. Diabetes Care, 2007; 30:2928–2933.
39.
AbbasiF, BrownBWJr., LamendolaC, et al.Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol, 2002; 40:937–943.
GrundySM, BrewerHBJr., CleemanJI, et al.Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 2004; 109:433–438.
42.
AlexanderCM, LandsmanPB, GrundySM. The influence of age and body mass index on the metabolic syndrome and its components. Diabetes Obes Metab, 2008; 10:246–250.
43.
MullerMJ, WillmannO, RiegerA, et al.Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology, 1992; 102:2033–2041.
44.
AdamsPC, PassmoreL, ChakrabartiS, et al.Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol, 2006; 4:918–923.
45.
MokdadAH, FordES, BowmanBA, et al.Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA, 2003; 289:76–79.
46.
ActonRT, BartonJC, PassmoreLV, et al.Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Diabetes Care, 2006; 29:2084–2089.
47.
CowieCC, RustKF, Byrd-HoltDD, et al.Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care, 2010; 33:562–568.
48.
RullR, SchumacherRJr.The arthropathy of hemochromatosis. In BartonJC, EdwardsCQ (eds): Hemochromatosis: Genetics, pathophysiology, diagnosis and treatment. Cambridge: Cambridge University Press. 2000:258–267.
49.
Nieves-PlazaM, Castro-SantanaLE, FontYM, et al.Association of hand or knee osteoarthritis with diabetes mellitus in a population of Hispanics from Puerto Rico. J Clin Rheumatol, 2013; 19:1–6.
50.
DubreuilM, RhoYH, ManA, et al.Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: A UK population-based cohort study. Rheumatology (Oxford), 2014; 53:346–352.
51.
RossJM, KowalchukRM, ShaulinskyJ, et al.Association of heterozygous hemochromatosis C282Y gene mutation with hand osteoarthritis. J Rheumatol, 2003; 30:121–125.
52.
LiC, FordES, ZhaoG, et al.Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005–2006. Diabetes Care, 2009; 32:342–347.
53.
LorenzoC, HanleyAJ, HaffnerSM. Differential white cell count and incident type 2 diabetes: The insulin resistance atherosclerosis study. Diabetologia, 2014; 57:83–92.
54.
WooSJ, AhnSJ, AhnJ, et al.Elevated systemic neutrophil count in diabetic retinopathy and diabetes: A hospital-based cross-sectional study of 30,793 Korean subjects. Invest Opthalmol Vis Sci, 2011; 52:7697–7703.
55.
EsserN, Legrand-PoelsS, PietteJ, et al.Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract, 2014; 105:141–150.
56.
MainousAGIII, KingDE, PearsonWS, et al.Is an elevated serum transferrin saturation associated with the development of diabetes?. J Fam Pract, 2002; 51:933–936.
HuthC, BeuerleS, ZiererA, et al.Biomarkers of iron metabolism are independently associated with impaired glucose metabolism and type 2 diabetes: The KORA F4 study. Eur J Endocrinol, 2015; 173:643–653.
59.
YeapBB, DivitiniML, GuntonJE, et al.Higher ferritin levels, but not serum iron or transferrin saturation, are associated with type 2 diabetes mellitus in adult men and women free of genetic haemochromatosis. Clin Endocrinol (Oxf), 2015; 82:525–532.
60.
AdamsLA, AnguloP, AbrahamSC, et al.The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis. Liver Int, 2006; 26:298–304.
61.
HeM, WorkalemahuT, MansonJE, et al.Genetic determinants for body iron store and type 2 diabetes risk in US men and women. PLoS One, 2012; 7:e40919.
62.
BeutlerE, FelittiV, HoNJ, et al.Relationship of body iron stores to levels of serum ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in patients with iron storage disease. Acta Haematol, 2002; 107:145–149.
63.
HerbertV, JayatillekeE, ShawS, et al.Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells, 1997; 15:291–296.
64.
NielsenP, GüntherU, DürkenM, et al.Serum ferritin iron in iron overload and liver damage: Correlation to body iron stores and diagnostic relevance. J Lab Clin Med, 2000; 135:413–418.
65.
CookJD, FinchCA, SmithNJ. Evaluation of the iron status of a population. Blood, 1976; 48:449–455.
LipschitzDA, CookJD, FinchCA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med, 1974; 290:1213–1216.
68.
ReissmanKR, DietrichM.R.On the presence of ferritin in the peripheral blood of patients with hepatocellular disease. J Clin Invest, 1956; 35:588–595.
69.
MatznerY, KonijnAM, HershkoC. Serum ferritin in hematologic malignancies. Am J Hematol, 1980; 9:13–22.
70.
RothwellRS, DavisP. Relationship between serum ferritin, anemia, and disease activity in acute and chronic rheumatoid arthritis. Rheumatol Int, 1981; 1:65–67.
71.
JacobsA. Serum ferritin and malignant tumours. Med Oncol Tumor Pharmacother, 1984; 1:149–156.
72.
MoirandR, LescoatG, DelamaireD, et al.Increase in glycosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawal. Alcohol Clin Exp Res, 1991; 15:963–969.
73.
PiñeroDJ, HuJ, CookBM, et al.Interleukin-1beta increases binding of the iron regulatory protein and the synthesis of ferritin by increasing the labile iron pool. Biochim Biophys Acta, 2000; 1497:279–288.
74.
JehnM, ClarkJM, GuallarE. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care, 2004; 27:2422–2428.
75.
Abril-UlloaV, Flores-MateoG, Sola-AlberichR, et al.Ferritin levels and risk of metabolic syndrome: Meta-analysis of observational studies. BMC Public Health, 2014; 14:483.
76.
BozziniC, GirelliD, OlivieriO, et al.Prevalence of body iron excess in the metabolic syndrome. Diabetes Care, 2005; 28:2061–2063.
77.
BartonJC, BartonJC, ActonRT, et al.Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis. Clin Gastroenterol Hepatol, 2012; 10:412–416.
78.
StrohmeyerG, NiederauC. Diabetes mellitus and hemochromatosis. In BartonJC, EdwardsCQ (eds.): Hemochromatosis. Genetics, pathophysiology, diagnosis and treatment. Cambridge: Cambridge University Press. 2000:268–277.
79.
HatunicM, FinucaneFM, NorrisS, et al.Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metabolism, 2010; 59:1811–1815.
